Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Substitution of First Phase Insulin Response in Patient With Type 2 Diabetes.
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT00254085
- Locations
- 🇩🇰
Gentofte University Hospital, Hellerup, Denmark
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT00184665
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 708
- Registration Number
- NCT00184600
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT00184613
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-06-19
- Lead Sponsor
- Odense University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT00121966
- Locations
- 🇩🇰
Diabetes Research Center, Odense, Denmark
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 520
- Registration Number
- NCT00117780
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
- Conditions
- First Posted Date
- 2005-06-27
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00115973
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-03-23
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 389
- Registration Number
- NCT00106366
- Locations
- 🇵🇷
Novo Nordisk Investigational Site, Rio Piedras, Puerto Rico
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT00097071
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00097084
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Ängelholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.